Effects of CYP3A4 and P-glycoprotein inhibition or induction on the pharmacokinetics of ubrogepant in healthy adults: Two phase 1, open-label, fixed-sequence, single-center, crosso...

by Abhijeet Jakate, Ramesh Boinpally, Matthew Butler, Wendy Ankrom, Marissa F Dockendorf, Antonia Periclou
Published 2021-08-01

Digitally Enabled, Patient‐Centric Clinical Trials: Shifting the Drug Development Paradigm

by Marissa F. Dockendorf, Bryan J. Hansen, Kevin P. Bateman, Matthew Moyer, Jyoti K. Shah, Lisa A. Shipley
Published 2021-03-01

Safety, Tolerability, and Pharmacokinetics of the β‐Site Amyloid Precursor Protein‐Cleaving Enzyme 1 Inhibitor Verubecestat (MK‐8931) in Healthy Elderly Male and Female Subjects...

by Mark Forman, John Palcza, Jack Tseng, Julie A. Stone, Brittany Walker, Dennis Swearingen, Matthew D. Troyer, Marissa F. Dockendorf
Published 2019-09-01

Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults

by K. Chris Min, Walter K. Kraft, Phung Bondiskey, Francheska Colón‐González, Wen Liu, Jialin Xu, Deborah Panebianco, Lori Mixson, Marissa F. Dockendorf, Catherine Z. Matthews, Ramesh Boinpally
Published 2021-03-01

Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males

by Wendy Ankrom, Phung Bondiskey, Chi‐Chung Li, John Palcza, Wen Liu, Marissa F. Dockendorf, Catherine Matthews, Deborah Panebianco, Tom Reynders, John A. Wagner, Abhijeet Jakate, Sofie Mesens, Walter K. Kraft, Eugene E. Marcantonio
Published 2020-05-01